A single-center, self-controlled, single-arm pilot clinical trial to assess the effect of lamivudine (3TC) on neurocognitive impairment biomarkers and type-I IFN (interferon)-stimulated genes in the plasma of patients with Mild Cognitive Impairment (MCI)
This research study is testing a medicine called lamivudine in people who have Mild Cognitive Impairment (MCI) caused by Alzheimer’s disease. MCI means experiencing memory or thinking problems that are more noticeable than usual for your age, but not severe enough to stop you living independently. The study aims to find out if lamivudine can change certain substances in the blood that are linked to memory and thinking problems. We're looking at specific 'markers' to understand if the medicine has any effect. Most importantly, we're also checking carefully to make sure the medicine is safe and if people can take it without too many side effects. This is an early-stage study to explore if this medicine might be helpful in the future.
At a glance
What is this study about?
This research is looking into a medicine called lamivudine for people who have Mild Cognitive Impairment (MCI). MCI means you might be experiencing some changes in your memory or thinking abilities, like forgetting names or struggling to find words, more often than other people your age. For many, MCI can be an early sign of Alzheimer’s disease.
The study aims to see if lamivudine can make a difference to certain chemicals in the blood that are linked to how our brains work. These chemicals, sometimes called 'biomarkers', can give us clues about how the brain is affected in conditions like MCI. By checking these blood markers before and after taking the medicine, researchers hope to understand if lamivudine has any impact on the changes that happen in the brain with MCI.
Another very important part of this study is to check how safe lamivudine is and if people can take it without having too many unwanted side effects. Understanding both the potential effects on blood markers and the safety of the medicine is crucial at this early stage of research. The information gathered from this study will help doctors and scientists decide if lamivudine is worth looking at in larger studies for people with MCI.
Key takeaways
- This study is testing an existing medicine (lamivudine) for Mild Cognitive Impairment (MCI) linked to Alzheimer's.
- It's exploring if the medicine changes certain markers in the blood related to brain health.
- Safety and side effects of the medicine are a main focus.
- The study takes about 6 months.
- All participants will receive the active study medicine.
- It's an early-stage study, meaning we are exploring new uses for this medicine.
Who may be eligible?
This study is open to adults aged 18 years and older. There is no upper age limit for taking part.
Both men and women can participate in this research. The most important thing is that you have been diagnosed with Mild Cognitive Impairment (MCI) that is thought to be due to Alzheimer's disease.
Specific medical details will be checked by the study team to make sure it's safe and appropriate for you to join. This ensures the study is suitable for everyone involved.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Mild Cognitive Impairment (MCI)?
- Has your doctor told you your MCI might be due to Alzheimer's disease?
- Are you able to attend regular clinic visits and have blood tests?
What does participation involve?
If you decide to take part, you would receive the study medicine, lamivudine, in tablet form. You would take this medicine for a certain period. Throughout the study, you'll have regular visits to the clinic.
During these visits, the study team will carry out health checks, which will include blood tests. These blood tests are important for checking how the medicine might be affecting those specific chemicals in your blood and also for monitoring your general health and any side effects. The team will also monitor any changes in your health or any new symptoms you experience. The total duration of your participation in the study, from your first visit to your final check-up, is expected to be about 24 weeks (roughly 6 months).
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is Mild Cognitive Impairment (MCI)?
MCI means you have some memory or thinking difficulties that are more than usual for your age, but not severe enough to affect your daily life too much.
What is lamivudine?
Lamivudine is a medicine that has been used for other conditions, but in this study, we are exploring if it might help with MCI.
Will I definitely get the active drug?
Yes, in this particular study, everyone who takes part will receive the active medicine, lamivudine.
How long will I be in the study?
Your involvement in the study, from start to finish, will last for about 24 weeks, which is roughly 6 months.
What kind of tests will I have?
You will have regular blood tests to check certain chemicals in your blood and to monitor your general health and safety.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.